In-Silico screening of Pleconaril and its novel substituted derivatives with Neuraminidase of H1N1 Influenza strain

Abstract

BackgroundNeuraminidase (NA) is a prominent surface antigen of Influenza viruses, which helps in release of viruses from the host cells after replication. Anti influenza drugs such as Oseltamivir target a highly conserved active site of NA, which comprises of 8 functional residues (R118, D151, R152, R224, E276, R292, R371 and Y406) to restrict viral release from host cells, thus inhibiting its ability to cleave sialic acid residues on the cell membrane. Reports on the emergence of Oseltamivir resistant strains of H1N1 Influenza virus necessitated a search for alternative drug candidates. Pleconaril is a novel antiviral drug being developed by Schering-Plough to treat Picornaviridae infections, and is in its late clinical trials stage. Since, Pleconaril was designed to bind the highly conserved hydrophobic binding site on VP1 protein of Picorna viruses, the ability of Pleconaril and its novel substituted derivatives to bind highly conserved hydrophobic active site of H1N1 Neuraminidase, targeting which oseltamivir has been designed was investigated.Result310 novel substituted variants of Pleconaril were designed using Chemsketch software and docked into the highly conserved active site of NA using arguslab software. 198 out of 310 Pleconaril variants analyzed for docking with NA active site were proven effective, based on their free binding energy.ConclusionPleconaril variants with F, Cl, Br, CH3, OH and aromatic ring substitutions were shown to be effective alternatives to Oseltamivir as anti influenza drugs.

Aureonitol, a Fungi-Derived Tetrahydrofuran, Inhibits Influenza Replication by Targeting Its Surface Glycoprotein Hemagglutinin

“…The binding site box was set to 25 × 25 × 25 Å to encompass the entire active site of the enzyme. The results were analyzed using PoseView software[ 41 , 42 ].…”

Antiviral activity of novel oseltamivir derivatives against some influenza virus strains.

“…In studies on antiviral drugs, two main approaches can be applied. The first one is an attempt to computerized design of molecules that should have high specificity and high efficiency against influenza viruses (Rungrotmongkol et al, 2009;Hussain Basha & Prasad, 2012;Wang et al, 2010;Durrant & McCammon, 2010;Park & Jo, 2010;Li et al, 2009;Mitrasinovic, 2009). However, this approach has limitations related to the difficulties in synthesizing newly designed molecules, their potential toxicity and lack of knowledge about potential metabolic transformations in the organism.…”

Pharmacophore feature-based virtual screening for finding potent GSK-3 inhibitors using molecular docking and dynamics simulations

“…Additionally, ligands were prepared by first removing the hybridization errors in the molecules and then adding the missing hydrogen bonds in order to check the fidelity of all bonds in the compounds. All prepared compounds were saved in the .mol format for further docking studies after a geometry optimization stage with the Universal Force Field (UFF) using a protocol similar to the protocols followed in previous studies [ 11 , 12 , 13 ]. The energy-scoring grid box was centered at the active ligand binding site location and its dimensions were set to 60 Å along each axis (x, y, and z).…”